Earnings Call Summary | Cardiff Oncology(CRDF.US) Q1 2023 Earnings Conference
Earnings Call Summary | Cardiff Oncology(CRDF.US) Q1 2023 Earnings Conference
The following is a summary of the Cardiff Oncology, Inc. (CRDF) Q1 2023 Earnings Call Transcript:
以下是加的夫腫瘤學公司（CRDF）2023年第一季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Cardiff Oncology reported a total of $67.2 million in cash and short-term investments as of March 31, 2024.
The company's cash burn in Q1 2024 was $7.7 million, projecting sufficient funds to support the company's operations until the third quarter of 2025.
加的夫腫瘤學報告稱，截至2024年3月31日，現金和短期投資總額爲6,720萬美元。
該公司在2024年第一季度的現金消耗爲770萬美元，預計在2025年第三季度之前有足夠的資金支持公司的運營。
Business Progress:
業務進展：
Cardiff Oncology has made notable progress in its CRDF-004 trial for RAS mutated metastatic colorectal cancer (mCRC).
The company expects data readouts from the trial in Q3/Q4 2024, and plans to increase its activated clinical trial sites to 35.
The recent presentation at the American Association for Cancer research included promising data for their oncology drug, onvansertib, in various cancers.
The company is considering further clinical trials in RAS wild type mCRC and is exploring treatments for ovarian cancer.
加的夫腫瘤學在 RAS 突變轉移性結直腸癌 (mCRC) 的 CRDF-004 試驗中取得了顯著進展。
該公司預計，該試驗的數據將在2024年第三季度/第四季度公佈，並計劃將其激活的臨床試驗地點增加到35個。
美國癌症研究協會最近發表的演講包括其腫瘤藥物onvansertib在各種癌症中的前景數據。
該公司正在考慮對RAS野生型mCRC進行進一步的臨床試驗，並正在探索卵巢癌的治療方法。
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由 AI 生成。無法完全保證內容的準確性。欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。